Physician profile
Daniel Finney
NPI 1225050156
$4,378.15
in general payments reported to CMS, 2019-2025
34 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $802 · 2022: $686 · 2023: $780 · 2024: $996 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.21 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $687.54 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $418.85 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $241.55 | 2021-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.99 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $198.59 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $196.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $180.34 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $161.47 | 2021-2025 | |
| Abbott Laboratories | $138.75 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $127.09 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.34 | 2022-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $109.67 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $109.17 | 2023-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $91.19 | 2024-2025 | Unithroid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $83.77 | 2023-2024 | Crysvita |
| Eisai INC. | $61.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.34 | 2021-2022 | |
| Viatris Specialty LLC | $53.64 | 2025 | Yupelri |
| Mylan Specialty L.P. | $52.46 | 2023-2024 | Yupelri |
| Boston Scientific Corporation | $42.96 | 2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $39.58 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.80 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $35.49 | 2021-2023 | Trintellix |
| Medtronic, INC. | $27.35 | 2025 | Progrip |
| Phathom Pharmaceuticals, INC. | $21.97 | 2025 | Voquezna |
| Zoll Respicardia, INC. | $20.31 | 2023 | Remede System |
| Impulse Dynamics (USA) INC. | $20.25 | 2023 | Optimizer |
| Lucid Diagnostics INC. | $17.39 | 2022 | |
| Inspire Medical Systems, INC. | $16.78 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $16.23 | 2024 | Gvoke Hypopen |
| Digestive Care, INC. | $15.85 | 2024 | Pertzye |
| Paratek Pharmaceuticals, INC. | $14.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Finney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.